Protective role of intravesical BCG in COVID-19 severity
| العنوان: | Protective role of intravesical BCG in COVID-19 severity |
|---|---|
| المؤلفون: | Ignacio F. San Francisco, Hector Gallegos, Pablo A. Rojas, Álvaro Zúñiga, Francisca Sepúlveda |
| المصدر: | BMC Urology BMC Urology, Vol 21, Iss 1, Pp 1-4 (2021) |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Male, medicine.medical_specialty, Urology, lcsh:RC870-923, Severity of Illness Index, Cohort Studies, 03 medical and health sciences, Intravesical BCG, 0302 clinical medicine, Adjuvants, Immunologic, Internal medicine, Severity of illness, Case fatality rate, Medicine, Humans, Cumulative incidence, Chile, Aged, Aged, 80 and over, business.industry, Incidence (epidemiology), Incidence, Case-control study, COVID-19, General Medicine, lcsh:Diseases of the genitourinary system. Urology, Exact test, 030104 developmental biology, Administration, Intravesical, Reproductive Medicine, Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Case-Control Studies, BCG Vaccine, Female, business, Non-muscle invasive bladder cancer, BCG vaccine, Cohort study, Research Article |
| الوصف: | Objectives To establish the role of BCG instillations in the incidence and mortality of COVID-19. Patients and methods NMIBC patients in instillations with BCG (induction or maintenance) during 2019/2020 were included, establishing a COVID-19 group (with a diagnosis according to the national registry) and a control group (NO-COVID). The cumulative incidence (cases/total patients) and the case fatality rate (deaths/cases) were established, and compared with the national statistics for the same age group. T-test was used for continuous variables and Fisher's exact test for categorical variables. Results 175 patients were included. Eleven patients presented CIS (11/175, 6.3%), 84/175 (48.0%) Ta and 68/175 (38.9%) T1. Average number of instillations = 13.25 ± 7.4. One hundred sixty-seven patients (95.4%) had complete induction. Forty-three patients (cumulative incidence 24.6%) were diagnosed with COVID-19. There is no difference between COVID-19 and NO-COVID group in age, gender or proportion of maintenance completed. COVID-19 group fatality rate = 1/43 (2.3%). Accumulated Chilean incidence 70–79 years = 6.3%. Chilean fatality rate 70–79 years = 14%. Conclusions According to our results, patients with NMIBC submitted to instillations with BCG have a lower case-fatality rate than the national registry of patients between 70 and 79 years (2.3% vs. 14%, respectively). Intravesical BCG could decrease the mortality due to COVID-19, so instillation schemes should not be suspended in a pandemic. |
| تدمد: | 1471-2490 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e6a0c730b87f18013ef0bae0b6100b https://pubmed.ncbi.nlm.nih.gov/33785004 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....70e6a0c730b87f18013ef0bae0b6100b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712490 |
|---|